Nature Nanotechnology |
Nanoneedle start-ups are traversing the biotech valley of death — from fundamental university research into commercial development in advanced therapeutics and diagnostics. How can academics make the most of this opportunity?
In this interesting article, our CEO and founder Pascal Behr takes you along the journey of Cytosurge – from an ETH Zurich biotech spin-off to the company we are today. Learn more about how we got here and how FluidFM leveraged nanoneedle technology to become a unique single-cell manipulation tool that provides commercial solutions for areas like CRISPR cell line engineering and omics.